“Infusion Devices market set to grow to $2.9bn by 2022” says new Visiongain report

16 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Infusion Devices Market Forecast 2018-2028: Syringe, Insulin, Volumetric, Ambulatory, Patient Controlled Analgesia, Implantable, Enteral, Gastroenterology, Diabetes, Analgesia & Pain Management, Chemotherapy, Paediatrics & Neonatology, Hospital, Home Healthcare, Ambulatory Surgical Centres

Infusion devices can be used to treat a wide range of therapeutic areas including analgesia, chemotherapy, diabetes and clinical nutrition, thus making them an invaluable tool in modern medicine. With the advent of modern medical devices, the infusion pump market has become one of the fastest growing drug delivery segments within the market. This rapid growth is projected due to the nature of the illnesses which infusion pumps are used to treat. For example, both the cancer and diabetes markets are on the rise.

The lead analyst of the report commented "With improved regulations, new infusion pump systems hitting the market are safer, more effective, and are becoming increasingly technologically advanced. This has come at a time when a shift between hospital and home care is happening across the world, though particularly in Europe.

The shift in demand from hospitals to home care settings has been particularly advantageous for insulin pumps, patient-controlled analgesia pumps, and ambulatory pumps due to the increased acceptance by patients and focus for the reduction of overall treatment costs associated with longer hospital stays."

Leading companies featured in the report include Baxter International Inc., B. Braun Melsungen AG, Becton, Dickinson and Company, CME Medical UK Ltd., Fresenius SE & Co. KGaA, ICU Medical, Inc., Johnson & Johnson, Moog Inc., Smiths Group plc, Terumo Medical Corporation

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Rare Diseases Market Report 2021-2031

As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.

02 March 2021

Read

Visiongain Publishes Respiratory Inhalers Market Report 2021-2031

Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.

26 February 2021

Read

Visiongain Publishes Bile Duct Cancer Drugs Market Report to 2031

The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.

22 February 2021

Read

Visiongain Publishes Big Data Analytics in Healthcare Market Report to 2031

The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.

22 February 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever